Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial

20262 citationsJournal Articlehybrid Open Access

Authors

ClinicalTrials.gov NCT03813784.

Published in: BMJ

Volume 392, pp. e086115-e086115

Field-Weighted Citation Impact: 89.47